Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's
- Written by PR Newswire
Composition of Matter Patent Covers More than 80 Novel Compounds
![]() |
MELBOURNE, Australia and SAN FRANCISCO, Jan. 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the...